Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | KDM4B | O94953 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22119382 | 0.98 | PARP1 (0.41) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| 2-Methoxyethanol SCHEMBL7416777 | 0.83 | HPRT1 (0.36) | ADORA3 | |
| SCHEMBL5748106 | 0.68 | — | — | |
| SCHEMBL11263950 | 0.67 | MKNK1 (0.53) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Allopurinol SCHEMBL3739112 | 0.67 | ALDH1A1 (0.50) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL4818670 | 0.65 | ELANE (0.37) | — | |
| Allopurinol SCHEMBL2565655 | 0.65 | ALDH1A1 (0.48) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL7014725 | 0.65 | KDM4A (0.50) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL325052 | 0.65 | PARP1 (0.55) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL30787886 | 0.65 | PARP1 (0.43) | PARP1PDPK1CA12ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017060488-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2017-04-13 | — | — | WO | claimed |
| EP-3099689-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2016-12-07 | — | — | EP | claimed |
| WO-2015114647-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-08-06 | — | — | WO | claimed |
| WO-2014024125-A1 | PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE DERIVATIVES AS PDE9 INHIBITORS | CELON PHARMA S.A. (PL) | 2014-02-13 | — | — | WO | claimed |
| WO-2008071650-A2 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-19 | — | — | WO | claimed |
| EP-1368352-A1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | Pfizer Limited (GB) | 2003-12-10 | — | — | EP | claimed |
| EP-1296687-A2 | TREATMENT OF MALE SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | claimed |
| WO-2002074774-A1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2002-09-26 | — | — | WO | claimed |
| WO-2002003995-A2 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | claimed |
| EP-4630405-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2025-10-15 | — | — | EP | disclosed |
| CN-119677737-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119546580-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024123815-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-1220856-A2 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES | Pfizer Limited (GB) | 2002-07-10 | — | — | EP | disclosed |
| EP-1140044-A2 | cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION | Novartis AG (CH) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001027113-A2 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000037061-A2 | cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION | NOVARTIS AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| EP-0977756-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998049166-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 1998-11-05 | — | — | WO | disclosed |